Research Industry Presents United Front On Japan Reforms
Strong IP Waiver Opposition
Three groups representing the domestic and multinational research-based pharma industry in Japan present a unified position as they call for policy changes they see as providing the right environment for investment, innovation and a sustainable healthcare system.